Speciality: Nephrology
Description:
A warm welcome to all the medical professionals in this exciting session on evolving science in the space of CKD.
The global prevalence of CKD is substantial with profound implications, healthcare costs, and outcomes. The risk of morbidity and mortality rises sharply as CKD progresses. The vast majority of larger-scale trials in CKD have focussed on Type 2 Diabetes populations.
SGLT2 inhibition has a number of potential direct and downstream effects which may result in beneficial effects on kidney function. SGLT2i CVOTs have consistently shown a reduction in renal endpoints. DAPA-CKD builds upon the evidence for Dapagliflozin in preventing hHF and worsening renal disease in DECLARE and reducing the risk of worsening HF and CV death in DAPA-HF.
Therefore, listen to the webinar, grab the shared knowledge, and follow HiDoc for more such exciting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Nuclear missile workers are contracting cancer: They blame the bases
2.
Mixed Results With Cyclophosphamide in Mismatched Unrelated Stem Cell Transplants
3.
New analysis helps discern benign from malignant thyroid growths
4.
MCh in Gynecologic Oncology: Admission, Medical School, Fees, Qualifications Information
5.
Even a few mutated cells can significantly impact how blood cancers develop, study finds
1.
Uncovering the Hidden Signs: How to Recognize the Early Symptoms of Colon Cancer
2.
The benefits and risks of taking fludrocortisone for adrenal insufficiency
3.
IGSF8: A Rising Star in Cancer Immunotherapy - Harnessing the Innate Immune System
4.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
5.
Different Types of Blood Dyscrasias
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
2.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Further Discussion on A New Perspective
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
4.
Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.
5.
Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation